Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
2.55B | 1.96B | 1.35B | 907.96M | 1.02B | Gross Profit |
367.35M | 460.47M | 316.58M | 250.41M | 321.06M | EBIT |
-40.48M | -71.21M | -59.84M | 30.25M | -37.88M | EBITDA |
84.85M | -24.79M | 43.75M | 55.66M | -241.38M | Net Income Common Stockholders |
-61.62M | -113.04M | -18.70M | -30.28M | -334.25M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
163.50M | 192.82M | 188.20M | 266.28M | 340.49M | Total Assets |
2.54B | 2.68B | 1.82B | 1.42B | 1.37B | Total Debt |
713.67M | 644.80M | 476.12M | 280.47M | 359.78M | Net Debt |
609.47M | 451.97M | 287.92M | 14.19M | 19.29M | Total Liabilities |
1.54B | 1.61B | 957.88M | 725.83M | 750.59M | Stockholders Equity |
1.00B | 1.07B | 859.42M | 693.63M | 619.60M |
Cash Flow | Free Cash Flow | |||
-6.13M | 113.84M | -49.91M | 13.76M | -45.70M | Operating Cash Flow |
18.77M | 142.58M | -11.55M | 38.75M | -16.23M | Investing Cash Flow |
-62.93M | -415.54M | -259.12M | -15.79M | 261.07M | Financing Cash Flow |
-565.00K | 281.34M | 131.54M | -29.55M | -11.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.94B | ― | -0.25% | ― | 9.37% | 95.72% | |
67 Neutral | $1.45B | 68.86 | 1.73% | ― | 3.00% | ― | |
58 Neutral | $1.53B | ― | -15.97% | ― | 16.29% | 66.01% | |
58 Neutral | $575.59M | ― | -48.23% | ― | 14.99% | -35.83% | |
54 Neutral | $1.00B | ― | -10.99% | ― | 10.24% | 2.63% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
48 Neutral | $1.25B | ― | -54.49% | ― | -2.54% | -322.03% |
On June 5, 2025, Evolent Health‘s Board of Directors restructured its committees, appointing Brendan Springstubb to both the Audit and Compensation Committees, as part of a cooperation agreement with Engaged Capital. During the 2025 Annual Meeting, stockholders elected ten directors, ratified Deloitte & Touche LLP as the accounting firm, approved executive compensation for 2024, and amended the 2015 Omnibus Incentive Compensation Plan.
The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.
On June 3, 2025, Evolent Health‘s management will present at the William Blair 45th Annual Growth Stock Conference, reaffirming its 2025 revenue guidance of $2.06 billion to $2.11 billion and Adjusted EBITDA guidance of $135.0 million to $165.0 million. The company also expects to reaffirm its second quarter 2025 revenue guidance of $440.0 million to $470.0 million and Adjusted EBITDA guidance of $33.0 million to $40.0 million, consistent with previous guidance. Evolent Health highlights the challenges in reconciling non-GAAP Adjusted EBITDA to net income due to various adjustments related to non-core operations and other factors.
The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.
On April 16, 2025, Diane Holder announced she would not seek re-election to Evolent Health‘s Board of Directors at the upcoming annual meeting on June 5, 2025. Her decision was not due to any disagreement with the company. In response, the Board has nominated Shawn Guertin, a seasoned executive with extensive experience in the healthcare industry, to stand for election. Guertin’s nomination aligns with Evolent’s ongoing efforts to refresh its board with independent directors, aiming to enhance corporate governance and drive shareholder value.